2.17
+0.03(+1.40%)
Currency In USD
| Previous Close | 2.14 |
| Open | 2.14 |
| Day High | 2.26 |
| Day Low | 2.07 |
| 52-Week High | 2.59 |
| 52-Week Low | 0.65 |
| Volume | 361,861 |
| Average Volume | 506,275 |
| Market Cap | 149.59M |
| PE | -1.17 |
| EPS | -1.86 |
| Moving Average 50 Days | 2.07 |
| Moving Average 200 Days | 1.43 |
| Change | 0.03 |
If you invested $1000 in Opus Genetics, Inc. (IRD) 10 years ago, it would be worth $27,125 as of January 15, 2026 at a share price of $2.17. Whereas If you bought $1000 worth of Opus Genetics, Inc. (IRD) shares 1 year ago, it would be worth $1,682.17 as of January 15, 2026 at a share price of $2.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
- Multi-asset pipeline with significant targeted data readouts and milestones -- Two lead ophthalmic gene therapy programs in clinical trials with new data anticipated in 2026 -- Supplemental New Drug Application (sNDA) submitted for partnered presby
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in pa
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
GlobeNewswire Inc.
Dec 09, 2025 12:00 PM GMT
Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trialRESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company dev